ATE402933T1 - Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten - Google Patents

Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten

Info

Publication number
ATE402933T1
ATE402933T1 AT98958070T AT98958070T ATE402933T1 AT E402933 T1 ATE402933 T1 AT E402933T1 AT 98958070 T AT98958070 T AT 98958070T AT 98958070 T AT98958070 T AT 98958070T AT E402933 T1 ATE402933 T1 AT E402933T1
Authority
AT
Austria
Prior art keywords
beta
adrenoreceptor agonists
chromene derivatives
derivatives usable
new sulfonamide
Prior art date
Application number
AT98958070T
Other languages
English (en)
Inventor
Gaetan Ladouceur
Richard Connell
Jeremy Baryza
Ann-Marie Campbell
Timothy LEASE
James Cook
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE402933T1 publication Critical patent/ATE402933T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98958070T 1997-12-19 1998-11-17 Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten ATE402933T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99458597A 1997-12-19 1997-12-19

Publications (1)

Publication Number Publication Date
ATE402933T1 true ATE402933T1 (de) 2008-08-15

Family

ID=25540825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98958070T ATE402933T1 (de) 1997-12-19 1998-11-17 Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten

Country Status (12)

Country Link
EP (1) EP1054881B1 (de)
JP (1) JP2001526281A (de)
AR (1) AR016691A1 (de)
AT (1) ATE402933T1 (de)
AU (1) AU751015B2 (de)
CA (1) CA2314925A1 (de)
CO (1) CO4990952A1 (de)
DE (1) DE69839821D1 (de)
IL (1) IL136688A0 (de)
TW (1) TW502032B (de)
WO (1) WO1999032475A1 (de)
ZA (1) ZA9810489B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256331A (ja) * 1999-01-08 2000-09-19 Nippon Bayer Agrochem Co Ltd テトラゾリノン誘導体および除草剤としてのその用途
ATE280167T1 (de) 1999-07-23 2004-11-15 Pfizer Prod Inc Zwischenprodukte und ein verfahren zur herstellung von beta3-adrenergischer rezeptor- agoniste
EA200300145A1 (ru) * 2000-07-13 2003-06-26 Эли Лилли Энд Компани АГОНИСТЫ β-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
CZ20013076A3 (cs) 2000-08-29 2002-04-17 Kuraray Co., Ltd. Způsob výroby chromankarboxylové kyseliny
EP1432696A1 (de) 2001-10-04 2004-06-30 Wyeth Chromanderivate als 5-hydroxytryptamin-6-liganden
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
US7034051B2 (en) 2003-08-28 2006-04-25 Adolor Corporation Fused bicyclic carboxamide derivatives and methods of their use
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives
CN102482228A (zh) 2009-07-17 2012-05-30 盐野义制药株式会社 含有内酰胺或苯磺酰胺化合物的药物
EP2536693A4 (de) 2010-02-17 2014-08-06 UNIVERSITé LAVAL Substituierte 2-imidazolidone und analoga
CN108218845B (zh) * 2016-12-21 2022-11-29 江苏柯菲平医药股份有限公司 一类色满-6-磺酰胺RORγ调节剂及其用途
CN112107583A (zh) * 2020-07-31 2020-12-22 东南大学 一种色满-6-磺酰胺RORγ调节剂的A晶型化合物的组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (de) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0801060A1 (de) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclische Beta-3 adrenergische Angonisten

Also Published As

Publication number Publication date
ZA9810489B (en) 1999-05-20
TW502032B (en) 2002-09-11
CO4990952A1 (es) 2000-12-26
AU1418399A (en) 1999-07-12
AR016691A1 (es) 2001-07-25
IL136688A0 (en) 2001-06-14
JP2001526281A (ja) 2001-12-18
EP1054881B1 (de) 2008-07-30
CA2314925A1 (en) 1999-07-01
EP1054881A1 (de) 2000-11-29
WO1999032475A1 (en) 1999-07-01
AU751015B2 (en) 2002-08-08
DE69839821D1 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
ID22891A (id) Komposisi farmasi untuk kombinasi piperidinoalkanol-dekongestan
EE200000155A (et) Taksoidide klassi kuuluvate derivaatide valmistamismeetod
ID19802A (id) Komposisi-komposisi berstruktur mikroskopik
BR9711970A (pt) Derivados 6,5-substitu¡do-heterobic¡clicos
CY2010002I1 (el) Στepεη φαρμακευτικη συνθεση πepιεχοντας παραγωγα βενζοφουρανιου
BR9808777B1 (pt) Composição dentifrícia dessensibilizadora de dois componentes.
ATE226578T1 (de) Benzofuranderivate als tachykininantagonisten
EP0984779A4 (de) Somatostatin agonisten
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
DE69807760D1 (de) Positiv-arbeitende Photoresistzusammensetzung
ID25508A (id) Komposisi dematologis
DE69733395D1 (de) Motorzusammensetzung
ATE184015T1 (de) Neue 19-nor-pregnen-derivate
DE69812475T2 (de) Photoresistzusammensetzung
EP0758898A4 (de) Activinantagonisten als verhütungsmittel
DE69824822D1 (de) Wässerige Antischaumzusammensetzungen
NO20001483D0 (no) Nye NPY-agonister
DE69714265D1 (de) Tetrahydrochinolinderivate als eaa antagonisten
ATE402933T1 (de) Neue sulfonamid-substituierte chroman-derivate verwendbar als beta 3 adrenorezeptor agonisten
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
DE69913697D1 (de) Naphtho- und dihydrobenzothiophenderivate als cytotoxische antitumormittel
ID17561A (id) Komposisi untuk pemakaian luar
DE69800779D1 (de) Photopolymerisierbare Zusammensetzung
MA26543A1 (fr) Derives de pyrrolopyrrolone comme inhibiteurs d'elastase de neutrophiles.
ID23250A (id) Komposisi paroksetin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties